Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good Old Fashion Tree Shake

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 17, 2020 12:21am

190 Views

Post# 32125790

RE:RE:RE:RE:RE:RE:RE:RE:Good Old Fashion Tree Shake

Keep in mind that the goal is to get to a US exchange at some point after the winter.
In order to do that, the shares have to go up.
The plan is to get the shares up.

I can't speak to the success of that goal ... but ... I would bet there's enough "good" news coming (at some point) to make that happen.

We have to let the company do its thing - nothing to do but worry now.

Hahaha!

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?